GAMMA Investing
NGNE icon

GAMMA Investing’s Neurogene NGNE Stock Holding History

GAMMA Investing’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$18.1K Buy
650
+105
+19% +$3.74K ﹤0.01% 3006
2026
Q2 		$17.1K Buy
545
+10
+2% +$275 ﹤0.01% 2928
2026
Q1 		$10.8K Buy
535
+127
+31% +$2.46K ﹤0.01% 3034
2025
Q4 		$8.4K Sell
408
-109
-21% -$2.71K ﹤0.01% 3051
2025
Q3 		$8.96K Buy
517
+214
+71% +$4.3K ﹤0.01% 2937
2025
Q2 		$4.53K Sell
303
-50
-14% -$785 ﹤0.01% 3164
2025
Q1 		$4.13K Buy
353
+219
+163% +$3.8K ﹤0.01% 3157
2024
Q4 		$3.06K Buy
+134
New +$4.99K ﹤0.01% 3085

Other funds holding NGNE

Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Eastern Bank
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
Essential Partners
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
Root Financial Partners
Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return
Fortitude Family Office
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
CoreCap Advisors
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

GAMMA Investing's NGNE Position: Q3 2026 in Review

GAMMA Investing increased its Neurogene (NGNE) stake by 19% in Q3 2026, buying an estimated $3.74K and bringing the position to 650 shares worth $18.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3006.

GAMMA Investing first reported a position in NGNE in Q4 2024 and has held it in 8 quarters since. 10 funds tracked by Wall St. Rank hold NGNE as of Q3 2026.

  • GAMMA Investing held 650 shares of Neurogene worth $18.1K as of Q3 2026.
  • GAMMA Investing bought 105 Neurogene shares in Q3 2026, an estimated $3.74K.
  • Neurogene made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3006 holding.
  • GAMMA Investing first reported a position in Neurogene in Q4 2024 and has held it in 8 quarters since.
  • 10 funds tracked by Wall St. Rank held Neurogene as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.